search
Back to results

Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder (SAM-SAD)

Primary Purpose

Seasonal Affective Disorder

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Ramelteon
Placebo
Sponsored by
Lehigh Valley Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Seasonal Affective Disorder focused on measuring Seasonal Affective Disorder, Ramelteon, Psychiatry, Randomized Controlled Trial, Hamilton Depression Rating Scale- SAD Version, Circadian Rhythm

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female age 18-65 yrs.
  • A diagnosis of seasonal affective disorder
  • A Pittsburgh Sleep Quality Index >5
  • English speaking
  • Be able to sign informed consent

Exclusion Criteria:

  • Active substance abuse
  • Current psychotic symptoms
  • Severe personality disorders
  • Primary sleep disorders
  • Severe chronic obstructive pulmonary disease (COPD)
  • Prescription fluvoxamine(Luvox) use

Sites / Locations

  • Lehigh Valley Hospital, Department of Psychiatry

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Ramelteon

Placebo

Arm Description

8 mg

Outcomes

Primary Outcome Measures

Sleep Satisfaction at Baseline and Measured Monthly, as Measured by the Pittsburgh Sleep Quality Index (PSQI)
Self-rated scale to measure quality of sleep via questions regarding sleep latency, duration, efficiency, disturbances, use of sleep medication, and daytime dysfunction. Score ranges from 0-21, higher scores represent more significant sleep disturbance.

Secondary Outcome Measures

Depressive Symptoms at Baseline and Measured Monthly, as Measured by the Zung Depression Scale (ZDS)
Self-rated scale to measure severity of depressive symptoms. Score ranges from 25-100, higher scores reflect more depression.
Depressive Symptoms at Baseline and Measured Monthly, as Measured by the Structured Interview Guide for the Hamilton Depression Rating - Seasonal Affective Disorder (SIGH-SAD)
Clinician-rated measure of mood; evaluates classical 21 Hamilton Depression items, and 8-item subscale measuring atypical depression symptoms which commonly occur during SAD episodes. Score ranges from 0-89, higher scores indicate higher levels of depression.

Full Information

First Posted
July 13, 2007
Last Updated
October 2, 2009
Sponsor
Lehigh Valley Hospital
Collaborators
Takeda Pharmaceuticals North America, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00502320
Brief Title
Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder
Acronym
SAM-SAD
Official Title
Randomized Placebo-Controlled Trial of Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
October 2009
Overall Recruitment Status
Completed
Study Start Date
September 2006 (undefined)
Primary Completion Date
April 2008 (Actual)
Study Completion Date
July 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Lehigh Valley Hospital
Collaborators
Takeda Pharmaceuticals North America, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine whether treating sleep difficulties in patients with seasonal affective disorder also improves their depressive symptoms.
Detailed Description
Seasonal affective disorder(SAD) is a type of depression in which a patient's depressive symptoms worsen in the winter. These patients' depressive symptoms often lessen in the spring and summer months. Much of the focus of the treatment of SAD (light therapy and melatonin) has involved the brain's suprachiasmatic nucleus(SCN), as it is hypothesized that one potential reason for SAD is a desynchronized SCN. Ramelteon offers a new and more pharmacologically exact mechanism to re-synchronize the SCN. The administration of ramelteon for this patient population may improve sleep, and in addition, do so in a manner that may also reduce their seasonal affective depressive symptoms. Patients eligible for enrollment will be administered either ramelteon or placebo and return to the study office for 4 monthly visits over the winter months, to evaluate the effects of ramelteon versus placebo on sleep and mood.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Seasonal Affective Disorder
Keywords
Seasonal Affective Disorder, Ramelteon, Psychiatry, Randomized Controlled Trial, Hamilton Depression Rating Scale- SAD Version, Circadian Rhythm

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ramelteon
Arm Type
Experimental
Arm Description
8 mg
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Ramelteon
Other Intervention Name(s)
Rozerem
Intervention Description
one 8 mg tablet at bed for up to 4 months
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
one tablet at bedtime for up to 4 months
Primary Outcome Measure Information:
Title
Sleep Satisfaction at Baseline and Measured Monthly, as Measured by the Pittsburgh Sleep Quality Index (PSQI)
Description
Self-rated scale to measure quality of sleep via questions regarding sleep latency, duration, efficiency, disturbances, use of sleep medication, and daytime dysfunction. Score ranges from 0-21, higher scores represent more significant sleep disturbance.
Time Frame
Monthly for duration of treatment (up to 4 months)
Secondary Outcome Measure Information:
Title
Depressive Symptoms at Baseline and Measured Monthly, as Measured by the Zung Depression Scale (ZDS)
Description
Self-rated scale to measure severity of depressive symptoms. Score ranges from 25-100, higher scores reflect more depression.
Time Frame
Monthly for duration of treatment (up to 4 months)
Title
Depressive Symptoms at Baseline and Measured Monthly, as Measured by the Structured Interview Guide for the Hamilton Depression Rating - Seasonal Affective Disorder (SIGH-SAD)
Description
Clinician-rated measure of mood; evaluates classical 21 Hamilton Depression items, and 8-item subscale measuring atypical depression symptoms which commonly occur during SAD episodes. Score ranges from 0-89, higher scores indicate higher levels of depression.
Time Frame
Monthly for duration of treatment (up to 4 months)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female age 18-65 yrs. A diagnosis of seasonal affective disorder A Pittsburgh Sleep Quality Index >5 English speaking Be able to sign informed consent Exclusion Criteria: Active substance abuse Current psychotic symptoms Severe personality disorders Primary sleep disorders Severe chronic obstructive pulmonary disease (COPD) Prescription fluvoxamine(Luvox) use
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Edward R. Norris, MD
Organizational Affiliation
Lehigh Valley Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Lehigh Valley Hospital, Department of Psychiatry
City
Allentown
State/Province
Pennsylvania
ZIP/Postal Code
18103
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
11513820
Citation
Avery DH, Eder DN, Bolte MA, Hellekson CJ, Dunner DL, Vitiello MV, Prinz PN. Dawn simulation and bright light in the treatment of SAD: a controlled study. Biol Psychiatry. 2001 Aug 1;50(3):205-16. doi: 10.1016/s0006-3223(01)01200-8.
Results Reference
background
PubMed Identifier
638392
Citation
Biggs JT, Wylie LT, Ziegler VE. Validity of the Zung Self-rating Depression Scale. Br J Psychiatry. 1978 Apr;132:381-5. doi: 10.1192/bjp.132.4.381.
Results Reference
background
PubMed Identifier
2748771
Citation
Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4.
Results Reference
background
PubMed Identifier
1947597
Citation
Buysse DJ, Reynolds CF 3rd, Monk TH, Hoch CC, Yeager AL, Kupfer DJ. Quantification of subjective sleep quality in healthy elderly men and women using the Pittsburgh Sleep Quality Index (PSQI). Sleep. 1991 Aug;14(4):331-8. Erratum In: Sleep 1992 Feb;15(1):83.
Results Reference
background
PubMed Identifier
17683643
Citation
Desan PH, Weinstein AJ, Michalak EE, Tam EM, Meesters Y, Ruiter MJ, Horn E, Telner J, Iskandar H, Boivin DB, Lam RW. A controlled trial of the Litebook light-emitting diode (LED) light therapy device for treatment of Seasonal Affective Disorder (SAD). BMC Psychiatry. 2007 Aug 7;7:38. doi: 10.1186/1471-244X-7-38.
Results Reference
background
PubMed Identifier
12957828
Citation
Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, Masana MI. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci. 2003 Sep 1;8:d1093-108. doi: 10.2741/1089.
Results Reference
background
PubMed Identifier
7594173
Citation
Gentili A, Weiner DK, Kuchibhatla M, Edinger JD. Test-retest reliability of the Pittsburgh sleep quality index in nursing home residents. J Am Geriatr Soc. 1995 Nov;43(11):1317-8. doi: 10.1111/j.1532-5415.1995.tb07415.x. No abstract available.
Results Reference
background
PubMed Identifier
15800134
Citation
Golden RN, Gaynes BN, Ekstrom RD, Hamer RM, Jacobsen FM, Suppes T, Wisner KL, Nemeroff CB. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry. 2005 Apr;162(4):656-62. doi: 10.1176/appi.ajp.162.4.656.
Results Reference
background
Citation
Hellpach, W.H. (1911). Die geopsychischen erschelnungen; Wetter und klima und landschaft in ihrem einfluss auf das seelenleben. Leipzig: W. Engelmann.
Results Reference
background
PubMed Identifier
4617659
Citation
Jenner FA. Chronobiology and the clinical psychiatrist: the current position. Chronobiologia. 1974 Apr-Jun;1(2):151-60. No abstract available.
Results Reference
background
PubMed Identifier
8526243
Citation
Lam RW, Gorman CP, Michalon M, Steiner M, Levitt AJ, Corral MR, Watson GD, Morehouse RL, Tam W, Joffe RT. Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. Am J Psychiatry. 1995 Dec;152(12):1765-70. doi: 10.1176/ajp.152.12.1765.
Results Reference
background
PubMed Identifier
12167524
Citation
Levitt AJ, Lam RW, Levitan R. A comparison of open treatment of seasonal major and minor depression with light therapy. J Affect Disord. 2002 Sep;71(1-3):243-8. doi: 10.1016/s0165-0327(01)00397-4.
Results Reference
background
PubMed Identifier
3394867
Citation
Lewy AJ, Sack RL. The phase-shift hypothesis of seasonal affective disorder. Am J Psychiatry. 1988 Aug;145(8):1041-3. doi: 10.1176/ajp.145.8.1041c. No abstract available.
Results Reference
background
PubMed Identifier
16648247
Citation
Lewy AJ, Lefler BJ, Emens JS, Bauer VK. The circadian basis of winter depression. Proc Natl Acad Sci U S A. 2006 May 9;103(19):7414-9. doi: 10.1073/pnas.0602425103. Epub 2006 Apr 28.
Results Reference
background
PubMed Identifier
9247266
Citation
Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK, Reppert SM. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron. 1997 Jul;19(1):91-102. doi: 10.1016/s0896-6273(00)80350-5.
Results Reference
background
PubMed Identifier
15992557
Citation
Manber R, Blasey C, Arnow B, Markowitz JC, Thase ME, Rush AJ, Dowling F, Koscis J, Trivedi M, Keller MB. Assessing insomnia severity in depression: comparison of depression rating scales and sleep diaries. J Psychiatr Res. 2005 Sep;39(5):481-8. doi: 10.1016/j.jpsychires.2004.12.003. Epub 2005 Jan 23.
Results Reference
background
PubMed Identifier
17395264
Citation
McClung CA. Circadian genes, rhythms and the biology of mood disorders. Pharmacol Ther. 2007 May;114(2):222-32. doi: 10.1016/j.pharmthera.2007.02.003. Epub 2007 Feb 28.
Results Reference
background
PubMed Identifier
11435265
Citation
Michalak EE, Wilkinson C, Dowrick C, Wilkinson G. Seasonal affective disorder: prevalence, detection and current treatment in North Wales. Br J Psychiatry. 2001 Jul;179:31-4. doi: 10.1192/bjp.179.1.31.
Results Reference
background
PubMed Identifier
17112403
Citation
Michalak EE, Murray G, Levitt AJ, Levitan RD, Enns MW, Morehouse R, Tam EM, Cheung A, Lam RW. Quality of life as an outcome indicator in patients with seasonal affective disorder: results from the Can-SAD study. Psychol Med. 2007 May;37(5):727-36. doi: 10.1017/S0033291706009378. Epub 2006 Nov 20.
Results Reference
background
PubMed Identifier
16271314
Citation
Modell JG, Rosenthal NE, Harriett AE, Krishen A, Asgharian A, Foster VJ, Metz A, Rockett CB, Wightman DS. Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL. Biol Psychiatry. 2005 Oct 15;58(8):658-67. doi: 10.1016/j.biopsych.2005.07.021.
Results Reference
background
PubMed Identifier
14504682
Citation
Moscovitch A, Blashko CA, Eagles JM, Darcourt G, Thompson C, Kasper S, Lane RM; International Collaborative Group on Sertraline in the Treatment of Outpatients with Seasonal Affective Disorders. A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. Psychopharmacology (Berl). 2004 Feb;171(4):390-7. doi: 10.1007/s00213-003-1594-8. Epub 2003 Sep 19.
Results Reference
background
PubMed Identifier
16041297
Citation
Pjrek E, Winkler D, Kasper S. Pharmacotherapy of seasonal affective disorder. CNS Spectr. 2005 Aug;10(8):664-9; quiz 672. doi: 10.1017/s1092852900019623.
Results Reference
background
PubMed Identifier
15892931
Citation
Postolache TT, Oren DA. Circadian phase shifting, alerting, and antidepressant effects of bright light treatment. Clin Sports Med. 2005 Apr;24(2):381-413, xii. doi: 10.1016/j.csm.2004.12.005.
Results Reference
background
PubMed Identifier
18762593
Citation
Praschak-Rieder N, Willeit M, Wilson AA, Houle S, Meyer JH. Seasonal variation in human brain serotonin transporter binding. Arch Gen Psychiatry. 2008 Sep;65(9):1072-8. doi: 10.1001/archpsyc.65.9.1072.
Results Reference
background
PubMed Identifier
17563165
Citation
Rohan KJ, Roecklein KA, Tierney Lindsey K, Johnson LG, Lippy RD, Lacy TJ, Barton FB. A randomized controlled trial of cognitive-behavioral therapy, light therapy, and their combination for seasonal affective disorder. J Consult Clin Psychol. 2007 Jun;75(3):489-500. doi: 10.1037/0022-006X.75.3.489.
Results Reference
background
PubMed Identifier
6581756
Citation
Rosenthal NE, Sack DA, Gillin JC, Lewy AJ, Goodwin FK, Davenport Y, Mueller PS, Newsome DA, Wehr TA. Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiatry. 1984 Jan;41(1):72-80. doi: 10.1001/archpsyc.1984.01790120076010.
Results Reference
background
PubMed Identifier
9723147
Citation
Ruhrmann S, Kasper S, Hawellek B, Martinez B, Hoflich G, Nickelsen T, Moller HJ. Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. Psychol Med. 1998 Jul;28(4):923-33. doi: 10.1017/s0033291798006813.
Results Reference
background
Citation
Thompson, C. (2001). Evidence-based treatment. In Seasonal Affective Disorder: Practice and Research (ed. T. Partonen and A. Magnusson), 151-158. New York: Oxford University Press.
Results Reference
background
PubMed Identifier
12462760
Citation
Thurber S, Snow M, Honts CR. The Zung Self-Rating Depression Scale: convergent validity and diagnostic discrimination. Assessment. 2002 Dec;9(4):401-5. doi: 10.1177/1073191102238471.
Results Reference
background
PubMed Identifier
14593433
Citation
Willeit M, Praschak-Rieder N, Neumeister A, Zill P, Leisch F, Stastny J, Hilger E, Thierry N, Konstantinidis A, Winkler D, Fuchs K, Sieghart W, Aschauer H, Ackenheil M, Bondy B, Kasper S. A polymorphism (5-HTTLPR) in the serotonin transporter promoter gene is associated with DSM-IV depression subtypes in seasonal affective disorder. Mol Psychiatry. 2003 Nov;8(11):942-6. doi: 10.1038/sj.mp.4001392.
Results Reference
background
Citation
William JBW, Link MJ, Rosenthal NE, Terman M. (1988). Structured Interview Guide for the Hamilton Depression Rating Scale, Seasonal Affective Disorders Version (SIGH-SAD). New York, New York State Psychiatric Institute
Results Reference
background
PubMed Identifier
14221692
Citation
ZUNG WW. A SELF-RATING DEPRESSION SCALE. Arch Gen Psychiatry. 1965 Jan;12:63-70. doi: 10.1001/archpsyc.1965.01720310065008. No abstract available.
Results Reference
background
PubMed Identifier
4381571
Citation
Zung WW. Factors influencing the self-rating depression scale. Arch Gen Psychiatry. 1967 May;16(5):543-7. doi: 10.1001/archpsyc.1967.01730230027003. No abstract available.
Results Reference
background
Citation
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000.
Results Reference
background

Learn more about this trial

Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder

We'll reach out to this number within 24 hrs